Expression of MUM1, BCL-6 and CD138/syn-1 in HIV-related Hodgkin lymphomas
| Case . | Diagnosis . | Immunohistochemistry . | EBV . | |||
|---|---|---|---|---|---|---|
| MUM14-150 . | BCL-64-150 . | syn-14-150 . | EBER . | LMP14-150 . | ||
| 1 | HL-NS | > 75 | − | > 75 | + | < 10 |
| 2 | HL-NS | > 75 | − | < 10 | − | − |
| 3 | HL-MC | > 75 | − | 25-50 | + | 25-50 |
| 4 | HL-MC | > 75 | − | 10-25 | − | − |
| 5 | HL-MC | > 75 | < 10 | 50-75 | + | > 75 |
| 6 | HL-MC | > 75 | − | > 75 | + | 25-50 |
| 7 | HL-MC | > 75 | − | > 75 | + | > 75 |
| 8 | HL-MC | > 75 | − | > 75 | + | 50-75 |
| 9 | HL-LD | > 75 | − | < 10 | + | > 75 |
| 10 | HL-LD | > 75 | − | < 10 | + | > 75 |
| 11 | HL-LD | > 75 | − | < 10 | + | 50-75 |
| 12 | HL-LD | > 75 | − | 25-50 | + | > 75 |
| 13 | HL-LD | > 75 | − | 25-50 | + | > 75 |
| 14 | HL-LD | > 75 | − | 50-75 | + | > 75 |
| 15 | HL-LD | > 75 | − | > 75 | − | − |
| 16 | HL-LD | > 75 | − | > 75 | + | > 75 |
| Case . | Diagnosis . | Immunohistochemistry . | EBV . | |||
|---|---|---|---|---|---|---|
| MUM14-150 . | BCL-64-150 . | syn-14-150 . | EBER . | LMP14-150 . | ||
| 1 | HL-NS | > 75 | − | > 75 | + | < 10 |
| 2 | HL-NS | > 75 | − | < 10 | − | − |
| 3 | HL-MC | > 75 | − | 25-50 | + | 25-50 |
| 4 | HL-MC | > 75 | − | 10-25 | − | − |
| 5 | HL-MC | > 75 | < 10 | 50-75 | + | > 75 |
| 6 | HL-MC | > 75 | − | > 75 | + | 25-50 |
| 7 | HL-MC | > 75 | − | > 75 | + | > 75 |
| 8 | HL-MC | > 75 | − | > 75 | + | 50-75 |
| 9 | HL-LD | > 75 | − | < 10 | + | > 75 |
| 10 | HL-LD | > 75 | − | < 10 | + | > 75 |
| 11 | HL-LD | > 75 | − | < 10 | + | 50-75 |
| 12 | HL-LD | > 75 | − | 25-50 | + | > 75 |
| 13 | HL-LD | > 75 | − | 25-50 | + | > 75 |
| 14 | HL-LD | > 75 | − | 50-75 | + | > 75 |
| 15 | HL-LD | > 75 | − | > 75 | − | − |
| 16 | HL-LD | > 75 | − | > 75 | + | > 75 |
HL indicates Hodgkin lymphoma; NS, nodular sclerosis; MC, mixed cellularity; LD, lymphocyte depletion.
Percentages of MUM1, BCL-6, syn-1, and LMP1+Reed-Sternberg cells were assigned to one of the following categories: 0%, less than 10%, 10% to 25%, 25% to 50%, 50% to 75%, and greater than 75%.